Dark Horse Consulting Group and Porton Advanced Announce Memorandum of Understanding Providing a Streamlined Path to Conducting IITs in China

WALNUT CREEK, Calif. and SUZHOU, China, April 27 (Bernama) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), today announced the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at accelerating the development and clinical translation of cell and gene therapies globally.

This partnership unites DHCG's comprehensive regulatory, CMC, nonclinical, clinical, quality & compliance, supply chain, commercial launch, and business analytics consulting capabilities with Porton Advanced's end-to-end GMP manufacturing infrastructure, spanning lentiviral vectors, AAV, mRNA/LNP, plasmids, and engineered cell therapies including CAR-T, CAR-NK, and iPSC-derived products. Together, the two organizations will offer client companies a cost-effective and rapid pathway into clinical-stage manufacturing, with particular emphasis on enabling Investigator-Initiated Trials (IITs) in China.